Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R. Clamp, Jonathan A. Ledermann, Jae-Won Kim et al.|The Lancet Oncology|2022Cited by 45
Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatmentAndrew R. Clamp, Jonathan A. Ledermann, Iain A. McNeish et al.|Annals of Oncology|2018Cited by 5